Please use this identifier to cite or link to this item:
Title: Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
Authors: SAAD, Carla G. S.RIBEIRO, Ana C. M.MORAES, Julio C. B.TAKAYAMA, LiliamGONCALVES, Celio R.RODRIGUES, Marcelo B.OLIVEIRA, Ricardo M. deSILVA, Clovis A.BONFA, EloisaPEREIRA, Rosa M. R.
Citation: ARTHRITIS RESEARCH & THERAPY, v.14, n.5, article ID R216, 8p, 2012
Abstract: Introduction: Sclerostin levels have been reported to be low in ankylosing spondylitis (AS), but there is no data regarding the possible role of this Wnt inhibitor during anti-tumor necrosis factor (TNF) therapy. The present study longitudinally evaluated sclerostin levels, inflammatory markers and bone mineral density (BMD) in AS patients under anti-TNF therapy. Methods: Thirty active AS patients were assessed at baseline, 6 and 12 months after anti-TNF therapy regarding clinical parameters, inflammatory markers, BMD and baseline radiographic damage (mSASSS). Thirty age-and sex-matched healthy individuals comprised the control group. Patients' sclerostin levels, sclerostin binding low-density lipoprotein receptor-related protein 6 (LRP6) and BMD were evaluated at the same time points and compared to controls. Results: At baseline, AS patients had lower sclerostin levels (60.5 +/- 32.7 vs. 96.7 +/- 52.9 pmol/L, P = 0.002) and comparable sclerostin binding to LRP6 (P = 0.387) than controls. Improvement of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Ankylosing Spondylitis quality of life (ASQoL) was observed at baseline vs. 6 vs. 12 months (P < 0.01). Concomitantly, a gradual increase in spine BMD (P < 0.001) and a positive correlation between baseline mSASSS and spine BMD was found (r = 0.468, P < 0.01). Inflammatory parameters reduction was observed comparing baseline vs. 6 vs. 12 months (P < 0.01). Sclerostin levels progressively increased [baseline (60.5 +/- 32.7) vs. 6 months (67.1 +/- 31.9) vs. 12 months (72.7 +/- 32.3) pmol/L, P < 0.001]. At 12 months, the sclerostin levels remained significantly lower in patients compared to controls (72.7 +/- 32.3 vs. 96.70 +/- 52.85 pmol/L, P = 0.038). Moreover, sclerostin serum levels at 12 months were lower in the 10 patients with high C reactive protein (CRP) (>= 5 mg/l) compared to the other 20 patients with normal CRP (P = 0.004). Of note, these 10 patients with persistent inflammation also had lower sclerostin serum levels at baseline compared to the other patients (P = 0.023). Univariate logistic regression analysis demonstrated that AS patients with lower sclerostin serum levels had an increased risk to have high CRP at 12 months (odds ratio = 7.43, 95% CI 1.23 to 45.01, P = 0.020) than those with higher sclerostin values. Conclusions: Persistent low sclerostin levels may underlie continuous inflammation in AS patients under anti-TNF therapy.
Appears in Collections:Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36
Artigos e Materiais de Revistas Científicas - LIM/41

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)346.56 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.